UNSPSC 51161535: Dimabefylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C16H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6V4Z7SX7S, chemically known as 7-(p-dimethylaminobenzyl)-1,3-dimethylxanthine but generally known as dimabefylline, which bears US NIH Compound Identifier 71646. European Medicines Agency schedules Dimabefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07149MIG. The term DIMABEFYLLINE is an International Non-Proprietary Name.

UNSPSC 51161535 Dimabefylline is a Commodity code representing pharmaceutical active ingredients and finished-dose forms that state and local health systems procure through multistate cooperative purchasing arrangements. Recent solicitations under this code focus on generic pharmaceuticals and over-the-counter products distributed across participating government facilities rather than the dimabefylline ingredient specifically; state and local procurement offices source these products via established manufacturer-to-wholesaler-to-facility supply chains that include regulatory compliance (FDA, cGMP, DSCSA), NDC tracking, and negotiated pricing structures. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances administering contracts on behalf of state agencies, county health systems, and municipal facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, seeking multiple awards for generic multi-source pharmaceuticals and OTC products with a proposal due date of March 26, 2026 and contract effectiveness of July 1, 2026. MMCAP extends purchasing authority to participating jurisdictions in Minnesota and Oregon and requires vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain minimum insurance coverage including $5,000,000 commercial general liability per occurrence and $2,000,000 network security liability, and comply with a 3 percent administrative fee structure. Evaluation weighs price competitiveness at 75 percent, with remaining points allocated to fixed pricing, administrative compliance, EDI capability, and agreement to the administrative fee. No specific dollar awards or set-asides are disclosed; vendors should anticipate performance penalties of $200 to $1,500 per violation for reporting delays or onboarding failures.